



**Hematopathology WHO on Hematopoietic/Lymphoid Tissues Diagnostic Challenges And Updates In Chronic Lymphoproliferative Disorder Of NK Cells - 5/23/2022**  
**5/23/2022 9:00:00 AM - 5/23/2022 10:00:00 AM**

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact [PEPInfo@mdanderson.org](mailto:PEPInfo@mdanderson.org).

**Learning Objectives:**

- 1 Understand and apply WHO Classification to patient specimens.
- 2 Apply ancillary techniques and integrate with morphologic findings of patient specimen; thereby, modifying diagnosis and direct therapeutic decisions.

**Accreditation:**

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**American Board of Pathology MOC Recognition Statement:**

This activity has been registered to offer credit in the American Board of Pathology's Continuing Certification program. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Lifelong Learning credits. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Commercial Support:**

No commercial support has been received for this activity.

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Sergej Konoplev, MD, PhD	Activity Co-Director	Nothing to disclose - 12/28/2021
L. Jeffrey Medeiros, MD	Activity Director	Nothing to disclose - 05/17/2022
Peter H Norman, MD, FRCPC FASA	CE Reviewer	Nothing to disclose - 10/06/2021
Min Shi, MD, PhD	Faculty	Nothing to disclose - 05/09/2022
Lianqun Qiu, MD, PhD	Other Planning Committee Member	Nothing to disclose - 01/06/2022

Xiaoqiong Wang, MD, PhD	Other Planning Committee Member	Nothing to disclose - 02/15/2022
-------------------------	------------------------------------	----------------------------------